The use of a monoclonal antibody treatment slashed COVID-19 mortality by 30%, according to an international study co-lead by a University of Colorado researcher.

Evusheld, a combination of two monoclonal antibodies, showed "remarkable" benefits in a global study involving more than 1,400 patients, UCHealth physician Adit Ginde said in a statement Wednesday.

Patients were treated either with the actual medicine or a placebo in hospitals in the United States, Europe, Singapore and Uganda. Twenty-nine of them were treated at UCHealth's University of Colorado Hospital, the system said.

Those who received the actual medicine versus those who received a placebo did not necessarily recover faster from COVID-19, the study's authors wrote. But it did cut 90-day mortality. 

"One out of every three patients who would have died without the treatment survived after receiving the treatment," Ginde said. "That's a remarkable signal for benefit and suggests that this and other similar treatments may save lives in patients with severe COVID-19."

Evusheld is also approved, under emergency rules, to be given to at-risk people, like those with compromised immune systems, before they're infected with COVID-19. Colorado, like the rest of the country, receives regular shipments of the drug from the federal government for distribution. 

Health reporter

Seth Klamann is the health reporter for the Gazette, focused on COVID-19, public health and substance use. He's a Kansas City native and a University of Missouri alum, with stops in Wyoming, Omaha and Milwaukee before moving to Denver.